-
Je něco špatně v tomto záznamu ?
Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens
M. Sustkova-Fiserova, P. Jerabek, T. Havlickova, K. Syslova, P. Kacer,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT13687
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1996-10-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
Psychology Database (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- endokanabinoidy metabolismus fyziologie MeSH
- extracelulární prostor účinky léků metabolismus MeSH
- ghrelin fyziologie MeSH
- glyceridy metabolismus MeSH
- glycin analogy a deriváty farmakologie MeSH
- krysa rodu rattus MeSH
- kyseliny arachidonové metabolismus MeSH
- morfin farmakologie MeSH
- narkotika farmakologie MeSH
- nucleus accumbens účinky léků metabolismus MeSH
- polynenasycené alkamidy metabolismus MeSH
- potkani Wistar MeSH
- receptory ghrelinu antagonisté a inhibitory MeSH
- receptory somatotropinu antagonisté a inhibitory MeSH
- stereotypní chování účinky léků MeSH
- triazoly farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
RATIONALE AND OBJECTIVES: In addition to dopamine, endocannabinoids are thought to participate in neural reward mechanisms of opioids. Number of recent studies suggests crucial involvement of ghrelin in some addictive drugs effects. Our previous results showed that ghrelin participates in morphine-induced changes in the mesolimbic dopaminergic system associated with reward processing. The goal of the present study was to test whether the growth hormone secretagogue receptor (GHS-R1A) antagonist JMV2959 was able to influence morphine-induced effects on anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) in the nucleus accumbens shell (NACSh). METHODS: We used in vivo microdialysis to determine changes in levels of AEA and 2-AG in the NACSh in rats following (i) an acute morphine dose (5, 10 mg/kg s.c.) with and without JMV2959 pretreatment (3, 6 mg/kg i.p.) or (ii) a morphine challenge dose (5 mg/kg s.c.) with and without JMV2959 (3, 6 mg/kg i.p.) pretreatment, administered during abstinence following repeated doses of morphine (5 days, 10-40 mg/kg). Co-administration of ghrelin (40 ug/kg i.p.) was used to verify the ghrelin mechanisms involvement. RESULTS: Pretreatment with JMV2959 significantly and dose-dependently reversed morphine-induced anandamide increases in the NACSh in both the acute and longer-term models, resulting in a significant AEA decrease. JMV2959 significantly intensified acute morphine-induced decreases in accumbens 2-AG levels and attenuated morphine challenge-induced 2-AG decreases. JMV2959 pretreatment significantly reduced concurrent morphine challenge-induced behavioral sensitization. JMV2959 pretreatment effects were abolished by co-administration of ghrelin. CONCLUSIONS: Our results indicate significant involvement of ghrelin signaling in morphine-induced endocannabinoid changes in the NACSh.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028038
- 003
- CZ-PrNML
- 005
- 20170522092131.0
- 007
- ta
- 008
- 161005s2016 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00213-015-4119-3 $2 doi
- 024 7_
- $a 10.1007/s00213-015-4119-3 $2 doi
- 035 __
- $a (PubMed)26507196
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Šustková, Magdaléna $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 34, Czech Republic. magdalena.sustkova@lf3.cuni.cz. $7 xx0074794
- 245 10
- $a Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens / $c M. Sustkova-Fiserova, P. Jerabek, T. Havlickova, K. Syslova, P. Kacer,
- 520 9_
- $a RATIONALE AND OBJECTIVES: In addition to dopamine, endocannabinoids are thought to participate in neural reward mechanisms of opioids. Number of recent studies suggests crucial involvement of ghrelin in some addictive drugs effects. Our previous results showed that ghrelin participates in morphine-induced changes in the mesolimbic dopaminergic system associated with reward processing. The goal of the present study was to test whether the growth hormone secretagogue receptor (GHS-R1A) antagonist JMV2959 was able to influence morphine-induced effects on anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) in the nucleus accumbens shell (NACSh). METHODS: We used in vivo microdialysis to determine changes in levels of AEA and 2-AG in the NACSh in rats following (i) an acute morphine dose (5, 10 mg/kg s.c.) with and without JMV2959 pretreatment (3, 6 mg/kg i.p.) or (ii) a morphine challenge dose (5 mg/kg s.c.) with and without JMV2959 (3, 6 mg/kg i.p.) pretreatment, administered during abstinence following repeated doses of morphine (5 days, 10-40 mg/kg). Co-administration of ghrelin (40 ug/kg i.p.) was used to verify the ghrelin mechanisms involvement. RESULTS: Pretreatment with JMV2959 significantly and dose-dependently reversed morphine-induced anandamide increases in the NACSh in both the acute and longer-term models, resulting in a significant AEA decrease. JMV2959 significantly intensified acute morphine-induced decreases in accumbens 2-AG levels and attenuated morphine challenge-induced 2-AG decreases. JMV2959 pretreatment significantly reduced concurrent morphine challenge-induced behavioral sensitization. JMV2959 pretreatment effects were abolished by co-administration of ghrelin. CONCLUSIONS: Our results indicate significant involvement of ghrelin signaling in morphine-induced endocannabinoid changes in the NACSh.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kyseliny arachidonové $x metabolismus $7 D001095
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a endokanabinoidy $x metabolismus $x fyziologie $7 D063388
- 650 _2
- $a extracelulární prostor $x účinky léků $x metabolismus $7 D005110
- 650 _2
- $a ghrelin $x fyziologie $7 D054439
- 650 _2
- $a glyceridy $x metabolismus $7 D005989
- 650 _2
- $a glycin $x analogy a deriváty $x farmakologie $7 D005998
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a morfin $x farmakologie $7 D009020
- 650 _2
- $a narkotika $x farmakologie $7 D009294
- 650 _2
- $a nucleus accumbens $x účinky léků $x metabolismus $7 D009714
- 650 _2
- $a polynenasycené alkamidy $x metabolismus $7 D053284
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptory ghrelinu $x antagonisté a inhibitory $7 D054440
- 650 _2
- $a receptory somatotropinu $x antagonisté a inhibitory $7 D011986
- 650 _2
- $a stereotypní chování $x účinky léků $7 D013239
- 650 _2
- $a triazoly $x farmakologie $7 D014230
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jeřábek, Pavel $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 34, Czech Republic. $7 xx0301063
- 700 1_
- $a Havlickova, Tereza $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 34, Czech Republic.
- 700 1_
- $a Syslová, Kamila $u Department of Organic Technology ICT, Laboratory of Medicinal Diagnostics, Technicka 5, Prague 6, 166 28, Czech Republic. $7 xx0145898
- 700 1_
- $a Kačer, Petr, $u Department of Organic Technology ICT, Laboratory of Medicinal Diagnostics, Technicka 5, Prague 6, 166 28, Czech Republic. $d 1969- $7 xx0081992
- 773 0_
- $w MED00003990 $t Psychopharmacology $x 1432-2072 $g Roč. 233, č. 3 (2016), s. 469-484
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26507196 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20170522092525 $b ABA008
- 999 __
- $a ok $b bmc $g 1166352 $s 952668
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 233 $c 3 $d 469-484 $e 20151028 $i 1432-2072 $m Psychopharmacology $n Psychopharmacology $x MED00003990
- GRA __
- $a NT13687 $p MZ0
- LZP __
- $a Pubmed-20161005